Solid STAIRWAY Leads Roche To Phase III Study Of Faricimab In Wet AMD Trial
Roche unveiled positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD).
You may also be interested in...
Regeneron's Less Frequent Eylea Dosing Makes Late Sprint Across FDA Finish Line
Regeneron's blockbuster AMD biologic Eylea improved its ability to compete with future longer-acting VEGF inhibitors with a label supporting every dosing every 12 weeks; the company's less frequent regimen cleared FDA five days after receiving a complete response letter.
Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win
Following the failure late last year of Regeneron's combination of Eylea with nesvacumab, a Phase II success for the Swiss major's RG7716 is a boost for the theory that a VEGF/Ang-2 combo therapy can transform the treatment of certain eye diseases.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.